$THLD new volume recovery $1.21 Website

New Post Public Reply Private Reply Replies (1) Message Board
PoemStone
$THLD new volume recovery $1.21

Website
threshold.png


Shares Outstanding 71.51M
Float 65.4M

% Held by Insiders 10.38%
% Held by Institutions 1 52.40%
Shares Short 292.39k
Short Ratio 0.49
Short % of Float 0.44%
Shares Short (prior month) 413.1k

Headlines
and Filings

Threshold Pharmaceuticals, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the United States. Its lead investigational small molecule is evofosfamide, which is in two Phase III clinical trials for the treatment of soft tissue sarcoma indication and advanced pancreatic cancer; Phase II clinical trials for treating non-squamous non-small cell lung cancer; Phase II clinical trials for advanced melanoma; and Phase I/II clinical trials for multiple myeloma. The company is also involved in the study of evofosfamide in investigator sponsored trials, including Phase I/II clinical trials for glioblastoma; Phase I clinical trials for advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors; Phase II clinical trials for glioblastoma and pancreatic neuroendocrine tumors; Phase I clinical trials for advanced solid tumors; and Phase I/II clinical trials for advanced kidney cancer or liver cancer. In addition, it engages in developing Tarloxotinib, an investigational hypoxia-activated EGFR tyrosine kinase inhibitor, which is in two Phase II clinical trials for patients with advanced non-squamous non-small cell lung cancer, as well as patients with squamous cell carcinomas of the head, neck, or skin; and [18F]-HX4, an investigational PET imaging agent for hypoxia. The company has a license and co-development agreement with Merck KGaA to co-develop and commercialize evofosfamide; license agreement with Auckland UniServices Ltd. for the development program based on Tarloxotinib; and license agreement with Eleison Pharmaceuticals, Inc. for the manufacture, development, and commercialization of glufosfamide for the treatment of cancer in humans and animals, as well as other uses. Threshold Pharmaceuticals, Inc. was founded in 2001 and is headquartered in South San Francisco, California.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chicken Salad Chick's Utah Expansion: The Next Course

Updated Category News Views 209

A New Serving in Spanish Fork Chicken Salad Chick is taking another bite out of the Utah market with the opening of its second location in Spanish Fork. On deck for a November 17 debut, this fast-casual chain is serving up not just chicken salad, but a hefty dose of Southern hospitality and promotional giveaways to boot. The big hook? Be among the first 100 patrons and...

Continue Reading
Good Springs Earns Spot on Inc.'s 2026 Founder List

Updated Category News Views 31

There's a badge of honor in the investment world that's not about the dollars and cents pouring in—it's about having founders trust you to take care of their business babies. Good Springs Capital just snagged one by being named to Inc.'s 2026 Founder-Friendly Investors list. Now, if you're thinking this is just some fancy accolade, let's chew over the real nuggets here....

Continue Reading
Bird-X Welcomes Doolittle to Elevate Sales Strategy

Updated Category News Views 105

Change in Flight: Bird-X Eyes Strategic Growth Well, here's one that might spread its wings wide. Emanuel Doolittle has joined Bird-X, Inc. as Director of Sales and Business Development. Now, let's not beat around the bush — Bird-X isn't a name you'd see thrown around daily stock talks, but it's stirring up interest in the pest control sector without question. Why...

Continue Reading
Hagerty Amplifies Profit Forecast Amid Premium Gains

Updated Category News Views 0

An Unyielding Growth Trajectory Hagerty, Inc. just unveiled its behemoth third quarter results for 2026 and they're nothing if not eye-popping. With a whopping 18% increase in written premium year-over-year to a towering $1,099 million, there's no mistaking Hagerty’s robust growth trajectory. And that's just one piece of the puzzle—earned premiums rocketed up by 42%...

Continue Reading
Wet Noses Innovates Human-Grade Pet Food at PLMA 2026

Updated Category News Views 115

Pet Food Revolution? Wet Noses Takes the PLMA Stage Okay, listen up, pet lovers and industry folks alike—seems like Wet Noses, that Washington-based veteran in the dog treat game, is shaking up the pet food world. After cruising through the pet aisle for almost three decades, they're making a splash at the PLMA 2026. Why should we care? Well, they’re pushing this...

Continue Reading
Novartis Pulls the Plug on BioArctic Agreement

Updated Category News Views 34

Novartis Drops BioArctic Like a Hot Potato Well, folks, it looks like Novartis has decided to pack up its bags and hightail it out of its collaboration with BioArctic AB. This ain't just any small piece of news—it's got ramifications that have folks in the biotech and healthcare sector scratching their heads and, probably, feeling a mixture of apprehension and...

Continue Reading
Truecaller's Strategic Shift: Recovery and Growth in 2026

Updated Category News Views 61

Grappling with Numbers: Truecaller's Q3 2026 Results A glance at Truecaller's latest report tells us they're banking on a strategic recovery.AOver their recent interim report covering January to September 2026, they disclose a modest 1% decrease in net sales reaching SEK 464 million. Now, if you scoop away the currency fluctuations, net sales climb by a soft 3% from Q2....

Continue Reading
Illumina's Role in Singapore's Precision Medicine Leap

Updated Category News Views 99

Singapore's Bold Step into Precision Medicine When it comes to revolutionizing healthcare, Singapore isn't content to sit on the sidelines. They've just thrown a serious hat into the ring with the SG-INSIGHT study, a cornerstone of their National Precision Medicine programme. And Illumina, Inc. (NASDAQ:ILMN) is right there in it, gearing up to sequence the genomes of...

Continue Reading
Elron Ventures Revamps Leadership to Boost Tech Focus

Updated Category News Views 7

Shaking Up the Leadership Roster The folks over at Elron Ventures are making some big moves, shifting the chess pieces on their leadership board in a bid to bolster their investment and M&A strategy. They're bringing in fresh blood and seasoned vets alike to navigate the rocky waters of Defense Tech, Deep Tech, Cybersecurity, and AI. You reckon they're onto something,...

Continue Reading
Restorative Getaways Aid Grieving Families, Offers Relief

Updated Category News Views 71

Finding Solace in Change: The Power of Stepping Away Grieving a lost child. It’s a trip to hell and back, and for many families, the journey feels endless. The press of everyday life—bills, jobs, commutes—offers no mercy. At times, stepping out of the blur might be the prime move toward healing, and that's where restorative getaways step in. Escaping the Everyday...

Continue Reading

Top 5 Most Recently Viewed Articles

Proficient Auto Logistics Shares Q3 Financial Outlook for 2024

Updated Category News Views 95

Proficient Auto Logistics Provides Financial Outlook for Q3 2024 Proficient Auto Logistics, Inc. (NASDAQ: PAL) has recently provided essential updates regarding its anticipated operating and financial metrics for the third quarter of the fiscal year 2024. As the company prepares for its upcoming conference call on November 8, 2024, it acknowledges the financial challenges...

Continue Reading
Allarity Therapeutics, Inc. Investors Urged to Explore Class Action

Updated Category News Views 138

Important Investor Action for Allarity Therapeutics, Inc. Investors in Allarity Therapeutics, Inc. (NASDAQ: ALLR) now have a notable opportunity to join a class action lawsuit. This lawsuit may benefit those who purchased securities during a specific time frame. The Rosen Law Firm, a well-known entity in this field, is stepping in to represent these investors, seeking to...

Continue Reading
TGS and Viridien Initiate Laconia Phase III OBN Survey Trials

Updated Category News Views 295

Unveiling the Laconia Phase III Survey TGS, renowned for its forward-thinking approach in energy data and intelligence, has partnered with Viridien to embark on an ambitious project known as the Laconia Phase III OBN survey. With a goal to enhance geological understanding in the Gulf of America, this survey covers around 150 OCS blocks and follows the preceding successful...

Continue Reading
Synergi Secures €2M Funding to Expand Energy Flexibility Solutions

Updated Category News Views 185

Synergi Raises €2 Million to Fuel Growth in Energy Flexibility Synergi, an innovative Finnish tech company, has successfully completed a €2 million seed funding round aimed at boosting its efforts in providing flexible energy solutions to consumers and utilities. With a focus on integrating renewable energy sources into the existing power systems, Synergi is committed...

Continue Reading
Joubert Law Firm Teams Up with LSU Star Chris Hilton Jr.

Updated Category News Views 172

Joubert Law Firm Announces New Partnership with Chris Hilton Jr. Joubert Law Firm is thrilled to share the news of its new strategic partnership with Chris Hilton Jr., an exceptional wide receiver for the LSU Tigers. This collaboration is designed to enhance community safety and engagement initiatives, demonstrating the powerful connection between athletics and community...

Continue Reading